Diversify Wealth Management LLC Purchases 191 Shares of Eli Lilly and Company (NYSE:LLY)

Diversify Wealth Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 4.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,683 shares of the company’s stock after purchasing an additional 191 shares during the period. Diversify Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,230,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Azzad Asset Management Inc. ADV increased its holdings in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock worth $1,411,000 after purchasing an additional 45 shares during the period. TCP Asset Management LLC acquired a new stake in Eli Lilly and Company during the first quarter worth about $201,000. Valley National Advisers Inc. increased its stake in Eli Lilly and Company by 2.9% during the first quarter. Valley National Advisers Inc. now owns 5,901 shares of the company’s stock valued at $4,591,000 after acquiring an additional 165 shares during the period. Lake Street Private Wealth LLC raised its holdings in Eli Lilly and Company by 5.7% in the 1st quarter. Lake Street Private Wealth LLC now owns 8,175 shares of the company’s stock valued at $6,360,000 after acquiring an additional 440 shares in the last quarter. Finally, Meadow Creek Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 112.4% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 4,161 shares of the company’s stock worth $3,237,000 after acquiring an additional 2,202 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 6.3 %

Shares of LLY opened at $846.90 on Thursday. The stock’s fifty day simple moving average is $916.20 and its 200-day simple moving average is $865.10. The firm has a market capitalization of $804.90 billion, a PE ratio of 124.73, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.53 by ($0.35). Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 14.05 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Finally, BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.